Analysis
Triveni Bio raised $65 million in a round co-led by Ascenta Capital and Janus Henderson Investors to advance its pipeline of antibody-based therapeutics targeting immunological and inflammatory diseases. The financing supports a category -- immunology and inflammation -- that consistently ranks among the largest and most commercially durable in pharma.
The round is notable as much for who's writing the check as for the science. Janus Henderson, a large public-markets asset manager, co-leading a private biotech round is a crossover signal -- the kind of investor that re-engages when it sees a path to public markets and durable value. After a brutal stretch for biotech financing, that participation matters.
“The round is notable as much for who's writing the check as for the science.”
In a week where AI, compute, and defense soaked up most of the capital, Triveni is a useful reminder that venture isn't monolithic. Differentiated therapeutic science still commands meaningful rounds, and the appetite for biotech -- particularly in proven, high-value disease areas -- appears to be recovering alongside the broader risk-on turn.